11 results about "Totipotent stem cell" patented technology

The utility model relates to stem cell collection technical field, concretely disclose a kind of collection device for subtotipotent stem cell, including filter cartridge, the bottom of filter cartridge is fixedly installed with closure, the top of filter cartridge is fixedly installed with input pipe, the bottom of filter cartridge is fixedly installed with discharge pipe, the outside of discharge pipe is provided with sterile collection bottle, the inside of filter cartridge is provided with filter assembly, the top of input pipe is provided with fixed dismounting assembly, the top of fixed dismounting assembly is provided with connecting pipe, the top of connecting pipe is fixedly installed with collection bag, this is used for the collection device of subtotipotent stem cell, flange bolt connection and pipe clamp sealing design are used in fixed dismounting assembly, both through rigid connection ensure pipeline stable, and sterile environment is formed using sealing washer to prevent pollution, and support quick dismounting replacement collection bag, and give consideration to sealing property, convenience and reuse requirement.

The application provides a non-coding RNA combination and application thereof in mouse totipotent stem cell induction, and relates to the technical field of biotechnology.The combination comprises: an enhancer RNA with a sequence as shown in SEQ ID NO:1 and SEQ ID NO:2, and a long-chain non-coding RNA with a sequence as shown in SEQ ID NO:3.The application discloses, for the first time, that the expression of the endogenous non-coding RNA combination is synergistically inhibited by using a CRISPR inhibition system, and the mouse embryonic stem cells can be efficiently promoted to transform into 2C-like cells.The application does not need to integrate an exogenous transcription factor, avoids the safety risk of the genome, overcomes the defect of non-specific off-target of a chemical small molecule by precise targeting, and significantly improves the induction efficiency of the 2C-like cells to about 9.09%.The application provides a safer, more efficient and controllable new strategy for stem cell fate reprogramming and early development research.

The invention provides a culture method for promoting conversion of mouse embryonic stem cells into totipotent stem cells. The cells can be kept in a brand new form and subcultured under the condition. According to the method adopted by the invention, an inhibitor WM-3825 of 2 mu M H4K16ac is added into a DMEM (Dulbecco Modified Eagle Medium) with a culture medium composition of 10% fetal calf serum according to a proportion of 1: 1000, the mouse embryonic stem cells can be normally cultured and passaged, the change of the totipotent gene is detected through real-time fluorescent quantitative PCR (Polymerase Chain Reaction), the expression of the totipotent related gene Dux is found to be obviously increased, and the expression of the mouse embryonic stem cells is obviously improved. Flow cytometry detection shows that the proportion of the totipotent stem cells is remarkably increased, and AP dyeing shows that the pluripotency of the mouse embryonic stem cells is reduced. The method starts from cell culture, and the method is possibly suitable for research on conversion from pluripotency to totipotency of embryonic stem cells of other mammals including human. By adding a small-molecule inhibitor WM-3825 of H4K16ac, a brand-new method for promoting conversion from the mouse pluripotent stem cells to the totipotent stem cells is established, and the 2-cell period of mouse embryonic development can be simulated in vitro through the culture system. The invention provides a new method for the generation of the totipotent stem cells, deepens the understanding of people on different states of the stem cells, and provides a new perspective for understanding an epigenetics mechanism between the conversion of the totipotent stem cells and the conversion of the pluripotent stem cells.

The present application provides a method for preparing human ovarian somatic cell-like cells. The present application establishes a method for preparing human ovarian somatic cell-like cells in vitro, which comprises stage-based culture based on human stem cells (including human pluripotent stem cells and human totipotent stem cells). The method of the present application can efficiently obtain functional human ovarian somatic cell-like cells, promote the differentiation ability of female germ stem cells (FGSC) cultured in vitro, and provide a new approach for assisted reproduction and treatment of infertility.

The present invention relates to a method for producing hematopoietic stem cells derived from totipotent stem cells, and a method for producing a humanized mouse model using the produced hematopoietic stem cells. According to one aspect, the method for producing hematopoietic stem cells can highly efficiently differentiate hematopoietic stem cells from totipotent stem cells without gene insertion, and optimal differentiation conditions have been confirmed by combining low molecular weight compounds and protein growth factors.

The invention provides a method for promoting induction of human totipotent stem cells, belongs to the technical field of biology, and particularly relates to a method for promoting induction of the human totipotent stem cells to the totipotent stem cells through OTX2 knockout or knockdown, the method comprises the following steps: S1, constructing an OTX2 knockout or knockout plasmid vector; s2, establishing a human pluripotent stem cell line with OTX2 knocked down or knocked out; and S3, inducing the human pluripotent stem cells of which the OTX2 is knocked down or knocked out into totipotent stem cells, which are also called 8-cell-like cells (8CLCs). According to the invention, the efficiency of inducing the human pluripotent stem cells into the totipotent stem cells can be improved, and the application of the totipotent stem cells in in-vitro blastocyst-like induction, in-vivo chimeric embryo formation and the like is provided.

The invention relates to the technical field of stem cell engineering and anti-aging biology, in particular to a histone modification regulation method based on placenta amnion sub-totipotent stem cells and an anti-aging preparation thereof. The regulation and control method comprises the following steps: separating and purifying healthy full-month caesarean section placenta amniotic membrane tissues, carrying out composite enzymolysis and flow cytometry screening to obtain CD105 < + >, CD73 < + > and CD45 <-> stem cells, and primarily culturing the CD105 < + >, CD73 < + > and CD45 <-> stem cells; the method comprises the following steps: determining histone methyltransferase MLL3 and demethylase JMJD3 as target spots through ChIP-seq, and determining H3K4me3 and H3K27me3 as target modification sites; an MLL3 activator CM-272 with the final concentration of 15 [mu] M and a JMJD3 inhibitor GSK-J4 with the final concentration of 10 [mu] M form a composite regulator, and induction culture is performed for 84 h under the conditions of 37 DEG C and 5% CO2; and carrying out Western Blot verification and screening on the stem cells meeting the standard. According to the anti-aging preparation, regulated stem cells are used as active ingredients, a sodium alginate-gelatin (2: 1) composite carrier, 5% mannitol and 1% human serum albumin protective agent are used as auxiliary materials, and the injection with the pH of 7.2-7.4 is prepared. The method is accurate in regulation and control, and the preparation is remarkable in anti-aging effect and low in immunological rejection risk.

The present application relates to the biomedical field, and particularly relates to a kind of omnipotent stem cell culture medium containing maternal factors.The present application first uses maternal factors and pomegranate seed active peptide extract jointly to prepare omnipotent stem cell culture medium, the maternal factors in the culture medium are selected from TPRX1, TPRXL, miR-302 and IL1 alpha combination, verified analysis, the above-mentioned joint existence synergies, can effectively improve the expression of omnipotent stem cell in Oct3 / 4 gene and cell cluster number, further promote the induction capacity of somatic cell to omnipotent stem cell, so that the production of large quantities of omnipotent stem cell can be induced, meanwhile, the present application uses omnipotent stem cell culture medium as fibroblast proliferation-promoting culture medium, can effectively promote fibroblast proliferation, and is beneficial to the application in wound healing.

The present disclosure relates to compositions, constructs and vectors for reprogramming cells into plasmacytoid dendritic cells or interferon type I-producing cells, methods and uses thereof. The present disclosure relates to the development of methods for making plasmacytoid dendritic cells or interferon type I-producing cells that promote antiviral and anti-tumoral immune responses from differentiated, multipotent or pluripotent stem cells by introducing and expressing isolated / synthetic transcription factors. More particularly, the disclosure provides methods for obtain plasmacytoid dendritic cells or interferon type I-producing cells by direct cellular reprogramming with the surprisingly use of combinations of specific transcription factors.

The present invention relates to methods of determining a potency state of an embryonic stem cell (ESC) in culture, comprising detecting the expression level of Negative Elongation Factor Complex Member A (Nelfa) in the ESC, and correlating the expression level of Nelfa with that of a reference sample to determine the potency state of the ESC. The present invention also provides methods of selecting totipotent-like ESCs from a population of ESCs in culture using an anti-Nelfa antigen binding protein, methods of inducing totipotency in an ESC in culture, methods of improving the reprogramming efficiency of a somatic cell into an induced pluripotent stem cell and methods of reprogramming a somatic cell into a totipotent stem cell by inducing Nelfa expression. Cells comprising an expression vector encoding Nelfa and kits for use in the methods of the invention are also provided.

The present disclosure relates to compositions, constructs and vectors for reprogramming cells into plasmacytoid dendritic cells or interferon type I-producing cells, methods and uses thereof. The present disclosure relates to the development of methods for making plasmacytoid dendritic cells or interferon type I-producing cells that promote antiviral and anti-tumoral immune responses from differentiated, multipotent or pluripotent stem cells by introducing and expressing isolated / synthetic transcription factors. More particularly, the disclosure provides methods for obtain plasmacytoid dendritic cells or interferon type I-producing cells by direct cellular reprogramming with the surprisingly use of combinations of specific transcription factors.